Gruppo Biokimica India Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 28-06-2024
- Paid Up Capital ₹ 1.67 Cr
as on 28-06-2024
- Company Age 13 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -5.81%
(FY 2020)
- Profit -202.39%
(FY 2020)
- Ebitda -134.83%
(FY 2020)
- Net Worth -36.07%
(FY 2020)
- Total Assets 7.67%
(FY 2020)
About Gruppo Biokimica India
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.67 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ravi Madival, Subbaramanaidu Allu, and Mauro Galli serve as directors at the Company.
- CIN/LLPIN
U24110TN2011PTC082910
- Company No.
082910
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Oct 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Gruppo Biokimica India Private Limited offer?
Gruppo Biokimica India Private Limited offers a wide range of products and services, including Raw and Processed Leather, Semi Finished Leather.
Who are the key members and board of directors at Gruppo Biokimica India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravi Madival  | Director | 01-Jun-2014 | Current |
| Subbaramanaidu Allu | Director | 18-Oct-2012 | Current |
Mauro Galli  | Director | 18-Nov-2013 | Current |
Financial Performance of Gruppo Biokimica India.
Gruppo Biokimica India Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 5.81% decrease. The company also saw a substantial fall in profitability, with a 202.39% decrease in profit. The company's net worth observed a substantial decline by a decrease of 36.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gruppo Biokimica India?
In 2019, Gruppo Biokimica India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Gruppo Biokimica India?
Gruppo Biokimica India has a workforce of 13 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gruppo Biokimica India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gruppo Biokimica India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
